Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis.
Files
(Published version)
Date
2024
Authors
Murray, G.M.
Griffith, N.
Sinnappurajar, P.
Al Julandani, D.A.
Clarke, S.L.N.
Hawley, D.P.
Choi, J.
Guly, C.M.
Ramanan, A.V.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Ocular Immunology and Inflammation, 2024; 32(4):442-446
Statement of Responsibility
G. M. Murray, N. Griffith, P. Sinnappurajar, D. A. Al Julandani, S. L. N. Clarke, D. P. Hawley, J. Choi, C. M. Guly, Athimalaipet V. Ramanan
Conference Name
Abstract
Background: Adalimumab has demonstrated efficacy in non-infectious uveitis. With the introduction of biosimilar agents such as Amgevita, we aimed to quantify efficacy and tolerability compared to Humira in a multi-centre UK cohort Methods: Patients identified from tertiary uveitis clinics in 3 centres, after institution-mandated switching was implemented. Results: Data collected for 102 patients, aged 2–75 years, with 185 active eyes. Following switch, rates of uveitis flare were not significantly different (13 events before, 21 after, p = .132). Rates of elevated intraocular pressure were decreased (32 before, 25 afterwards, p = .006) and dosing of oral and intra-ocular steroids was stable. Twenty-four patients (24%) requested to return to Humira, commonly due to pain from injection or technical difficulty with the device. Conclusion: Amgevita is safe and effective for inflammatory uveitis with non-inferiority to Humira. Significant numbers of patients requested to switch back due to side effects including injection site reactions.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2023 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.